Perpetual Ltd Invests $2 Million in Alnylam Pharmaceuticals, Inc. $ALNY

Perpetual Ltd acquired a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the fourth quarter, according to its most recent disclosure with the SEC. The fund acquired 5,039 shares of the biopharmaceutical company’s stock, valued at approximately $2,004,000.

A number of other hedge funds also recently made changes to their positions in the stock. Sara Bay Financial raised its stake in Alnylam Pharmaceuticals by 20.7% during the 4th quarter. Sara Bay Financial now owns 1,750 shares of the biopharmaceutical company’s stock worth $695,000 after acquiring an additional 300 shares during the period. LeConte Wealth Management LLC increased its stake in shares of Alnylam Pharmaceuticals by 14.8% in the fourth quarter. LeConte Wealth Management LLC now owns 604 shares of the biopharmaceutical company’s stock worth $240,000 after purchasing an additional 78 shares in the last quarter. Private Advisory Group LLC increased its stake in shares of Alnylam Pharmaceuticals by 51.9% in the fourth quarter. Private Advisory Group LLC now owns 2,155 shares of the biopharmaceutical company’s stock worth $857,000 after purchasing an additional 736 shares in the last quarter. Northwest Wealth Management LLC bought a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at $225,000. Finally, Eastern Bank bought a new stake in shares of Alnylam Pharmaceuticals during the 4th quarter valued at $42,000. 92.97% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

ALNY has been the subject of several recent analyst reports. Chardan Capital reaffirmed a “buy” rating and issued a $425.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 25th. Weiss Ratings upgraded Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Thursday, January 15th. Wells Fargo & Company dropped their price objective on Alnylam Pharmaceuticals from $479.00 to $376.00 and set an “equal weight” rating for the company in a research note on Tuesday, January 20th. Raymond James Financial reiterated an “outperform” rating and set a $472.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday, January 12th. Finally, Oppenheimer initiated coverage on Alnylam Pharmaceuticals in a research note on Wednesday, January 7th. They set an “outperform” rating and a $500.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $473.87.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ ALNY opened at $318.85 on Friday. The company has a market cap of $42.29 billion, a P/E ratio of 186.46 and a beta of 0.39. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $495.55. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.71 and a current ratio of 2.76. The firm’s fifty day moving average is $326.77 and its two-hundred day moving average is $395.18.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported $1.25 EPS for the quarter, missing the consensus estimate of $1.43 by ($0.18). Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The company had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $1.16 billion. During the same period last year, the company earned ($0.65) EPS. The firm’s revenue for the quarter was up 84.9% on a year-over-year basis. As a group, analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insider Transactions at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 9,577 shares of the company’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $362.86, for a total transaction of $3,475,110.22. Following the sale, the chief executive officer directly owned 78,411 shares of the company’s stock, valued at $28,452,215.46. This represents a 10.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 2,290 shares of the stock in a transaction that occurred on Tuesday, January 13th. The shares were sold at an average price of $370.33, for a total value of $848,055.70. Following the transaction, the executive vice president owned 21,264 shares of the company’s stock, valued at $7,874,697.12. This represents a 9.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 53,923 shares of company stock valued at $18,072,087 in the last ninety days. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.